Active ingredientPaltusotineCat. No. P-P008-001CAS 2172870-89-0Family · Pharmaceutical analytical standards
Paltusotine
An oral somatostatin receptor type 2 (SST2) agonist for acromegaly in adults, approved in the United States in 2025 and in the European Union in 2026. This family brings together the active ingredient.
Did you know?Unlike the classic somatostatin analogues, which are peptides, it is a non-peptide molecule: this is why it can be taken as a tablet.
Go to the active ingredient →Active ingredientPaltusotineCat. No. P-P008-001CAS 2172870-89-0No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.